Elastomeric parts for parenterals and for devices for pharmaceutical use —

Part 4: Biological requirements and test methods

The European Standard EN ISO 8871-4:2006 has the status of a British Standard

ICS 11.040.20



National foreword

This British Standard was published by BSI. It is the UK implementation of EN ISO 8871-4:2006.

The UK participation in its preparation was entrusted to Technical Committee CH/212, IVDs.

A list of organizations represented on CH/212 can be obtained on request to its secretary.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

Compliance with a British Standard cannot confer immunity from legal obligations.

This British Standard was published under the authority of the Standards Policy and Strategy Committee on 29 September 2006

© BSI 2006

Amendments issued since publication

Amd. No.	Date	Comments

ISBN 0 580 49229 X

EUROPEAN STANDARD

NORME EUROPÉENNE EUROPÄISCHE NORM

June 2006

EN ISO 8871-4

ICS 11.040.20

Supersedes EN ISO 8871:1997

English Version

Elastomeric parts for parenterals and for devices for pharmaceutical use - Part 4: Biological requirements and test methods (ISO 8871-4:2006)

Éléments en élastomère pour administration parentérale et dispositifs à usage pharmaceutique - Partie 4: Exigences biologiques et méthodes d'essais (ISO 8871-4:2006)

Elastomere Teile für Parenteralia und für Geräte zur pharmazeutischen Verwendung - Teil 4: Biologische Anforderungen und Prüfverfahren (ISO 8871-4:2006)

This European Standard was approved by CEN on 5 June 2006.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the Central Secretariat or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the Central Secretariat has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION COMITÉ EUROPÉEN DE NORMALISATION EUROPÄISCHES KOMITEE FÜR NORMUNG

Management Centre: rue de Stassart, 36 B-1050 Brussels

Foreword

This document (EN ISO 8871-4:2006) has been prepared by Technical Committee ISO/TC 76 "Transfusion, infusion and injection equipment for medical and pharmaceutical use" in collaboration with CMC.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by December 2006, and conflicting national standards shall be withdrawn at the latest by December 2006.

This document supersedes EN ISO 8871:1997.

According to the CEN/CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and United Kingdom.

Endorsement notice

The text of ISO 8871-4:2006 has been approved by CEN as EN ISO 8871-4:2006 without any modifications.

INTERNATIONAL STANDARD

ISO 8871-4

First edition 2006-06-15

Elastomeric parts for parenterals and for devices for pharmaceutical use —

Part 4:

Biological requirements and test methods

Éléments en élastomère pour administration parentérale et dispositifs à usage pharmaceutique —

Partie 4: Exigences biologiques et méthodes d'essai



Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 8871-4 was prepared by Technical Committee ISO/TC 76, *Transfusion, infusion and injection equipment for medical and pharmaceutical use.*

This first edition, together with parts 1, 2, 3 and 5, cancels and replaces ISO 8871:1990 and ISO 8871:1990/Amd.1:1995, which has been technically revised.

ISO 8871 consists of the following parts, under the general title *Elastomeric parts for parenterals and for devices for pharmaceutical use*:

- Part 1: Extractables in aqueous autoclavates
- Part 2: Identification and characterization
- Part 3: Determination of released-particle count
- Part 4: Biological requirements and test methods
- Part 5: Functional requirements and testing

Introduction

The pharmaceutical industry requires, to an increasing extent, concrete details from the rubber manufacturer about the biological status of rubber closures as far as elastomeric closures are used as primary packaging materials in direct contact with the medicinal products. This request has been taken into account by preparing Annexes A to D of this part of ISO 8871.

Tests presented in this part of ISO 8871 can be taken into account as a guideline if the question of biological safety arises in context with primary packaging materials for pharmaceutical products. The use of certain tests of Annex A to Annex D in case of special applications of the packaging material should be agreed upon between users and manufacturers.

Elastomeric parts for parenterals and for devices for pharmaceutical use —

Part 4:

Biological requirements and test methods

1 Scope

This part of ISO 8871 specifies biological requirements for elastomeric parts for parenterals and for devices for pharmaceutical use. It also specifies the test methods, i.e. it offers the extraction procedures for elastomeric parts, and it makes reference to relevant biological test instructions in Pharmacopoeias and standards.

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-5, Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity

USP, The United States Pharmacopeia, United States Pharmacopeial Convention, Inc., Rockville, MD, USA

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

3.1

bacterial endotoxins

lipo-polysaccharides from gram-negative bacteria

3.2

bioburden

population of viable microorganisms on or in product and/or a package

[ISO 11737-1:—, definition 3.1]

3.3

cytotoxicity

biological response of mammalian cell cultures in vitro using appropriate biological parameters to extracts of elastomeric parts

3.4

intracutaneous toxicity

local response to extracts of elastomeric parts after intracutaneous injections into rabbits

3.5

systemic toxicity

systemic response to extracts of elastomeric parts after injection into mice

4 Biological requirements

4.1 General

The elastomeric parts shall not release any substances that may adversely affect the therapeutic effectiveness and safety of the pharmaceutical solution, including those substances which can exhibit toxic or pyrogenic reactions.

Selection of tests and their interpretation to be used in biological evaluations should take into account the chemical composition of the materials, including the conditions of exposure as well as the nature, degree, frequency and duration of exposure of the material.

Cytotoxicity, systemic toxicity and intracutaneous toxicity shall be considered for type testing as material characteristics. Endotoxins and bioburden shall be considered for monitoring purposes.

4.2 Extractable bacterial endotoxins

The limit, specified as endotoxin units per square centimetre (EU/cm²) of elastomeric part or endotoxin units per millilitre (EU/ml) extractable endotoxins, shall be agreed upon between supplier and user.

The test method shall be validated.

NOTE Annex A includes an example of a test method for the determination of extractable bacterial endotoxins that can be used.

4.3 Bioburden

The limit, specified as colony-forming units per square centimetre (cfu/cm²) or cfu per elastomeric part, shall be agreed upon between supplier and user.

The bioburden method shall be validated.

NOTE ISO 11737-1 can be used as a guideline to establish and validate the method.

4.4 Toxicity

4.4.1 General

Materials shall be tested *in vitro* for cytotoxicity in accordance with 4.4.2. Materials that meet the requirements of this test are not required to undergo further testing. Materials that do not meet the requirements of this test shall be tested *in vivo* for systemic and intracutaneous toxicity in accordance with 4.4.3 and 4.4.4 respectively.

4.4.2 Cytotoxicity

The test shall be performed according to Annex B.

For assessment refer to the requirements specified in USP, chapter <87>, "Biological Reactivity Tests, In Vitro".

4.4.3 Intracutaneous toxicity

The test shall be performed according to Annex C.

For assessment, refer to the requirements specified in USP, chapter <88>, "Biological Reactivity Tests, In Vivo, Intracutaneous Test".

4.4.4 Systemic toxicity

The test shall be performed according to Annex D.

For assessment, refer to the requirements specified in USP, chapter <88>.

Annex A

(informative)

Test for extractable bacterial endotoxins

A.1 General

This Annex defines a conventional method for the extraction of bacterial endotoxins from the surface of elastomeric parts. The extractable bacterial endotoxins are determined according to the methods specified in USP, chapter <85>, "Bacterial Endotoxins Test" or Ph.Eur.^[2], chapter 2.6.14 "Bacterial Endotoxins".

A.2 Principle

The extraction is performed by shaking elastomeric parts in endotoxin-free water. The determination of extractable bacterial endotoxins is performed according to the methods specified in USP or Ph.Eur. using limulus amebocyte lysate (LAL) which has been obtained from horseshoe crab, *Limulus polyphemus*, and which has been prepared and characterized for use as an LAL reagent.

A.3 Reagents and materials

- A.3.1 Depyrogenated glassware/heat stable instruments (e.g. forceps).
- A.3.2 Endotoxin-free water.
- A.3.3 Endotoxin reagents as specified in USP or Ph.Eur.

A.4 Preparation of depyrogenated glassware and heat stable instruments

- A.4.1 Clean the glassware in a laboratory dish washer. Ensure that residual soap is completely removed.
- **A.4.2** Wrap the glassware in aluminium foil as follows:
- completely wrap test tubes;
- wrap only the neck part of sample containers;
- completely wrap forceps.
- **A.4.3** Depyrogenate the wrapped parts at appropriate conditions, e.g. at least 30 min at 250 °C.
- **A.4.4** After depyrogenation, keep the parts in the aluminium foil.

A.5 Extraction of the elastomeric parts

Aseptically transfer a number of elastomeric parts corresponding to a surface of (100 ± 10) cm² into a depyrogenated sample container. Carefully add 100 ml endotoxin-free water, protect with cover film and shake (orbital shaking) for 5 min at room temperature.

If the surface area of $(100 \pm 10) \, \text{cm}^2$ cannot be achieved, add $(1 \pm 0,1) \, \text{ml}$ for every additional square centimetre.

In case of elastomeric parts with barely accessible cavities, e.g. 13 mm freeze drying closures, flashballs, needle shields etc., it may be necessary to cut the parts before extraction in order to obtain adequate recoveries. If parts are cut, take into account the original surface area of the parts.

A.6 Expression of results

Express the results as EU/cm² elastomeric part or EU/ml extractable endotoxins.

Annex B

(normative)

Test for cytotoxicity

B.1 Principle

The following test is designed to determine the biological reactivity of mammalian cell cultures following contact with extracts of elastomeric parts.

For details of performing the biological test itself, see USP, chapter <87> or ISO 10993-5.

B.2 Preparation of extract

Prepare as specified for preparation of extracts in USP, chapter <87>, or in ISO 10993-5 using serum supplemented mammalian cell culture medium. Extract with a sample/medium ratio of 25 cm² per 20 ml for 24 h at (37 ± 1) °C.

B.3 Procedure

B.4.1

Follow the instructions specified in USP, chapter <87> or in ISO 10993-5.

no extensive cell lysis and empty areas between cells.

B.4 Expression of results

Express the results as follows:

_	cytotoxic;
	non-cytotoxic.
B.4	.2 The sample is considered to be non-cytotoxic if the following criteria have been met:
_	\leqslant 50 % of the cells are round and devoid of intracytoplasmic granules;

Annex C (normative)

Test for intracutaneous toxicity

C.1 Principle

The following test is designed to determine local responses and skin irritations to extracts of elastomeric parts by intracutaneous injections into rabbits.

For details of performing the biological test itself, see USP, chapter <88>.

C.2 Preparation of extract

Prepare as specified for preparation of extracts in USP, chapter <88> using 9 g/l NaCl solution.

C.3 Procedure

Follow the instructions specified in USP, chapter <88>.

C.4 Expression of results

- **C.4.1** Express the results as follows:
- toxic
- non-toxic
- C.4.2 For assessment, see USP, chapter <88>.

Annex D

(normative)

Test for systemic toxicity

D.1 Principle

The following test is designed to determine the systemic responses to the extracts of elastomeric parts by intravenous injections into mice.

For details of performing the biological test itself, see USP, chapter <88>.

D.2 Preparation of extract

Prepare as specified for preparation of extracts in USP, chapter <88>.

D.3 Procedure

Follow the instructions specified in USP, chapter <88>.

D.4 Expression of results

	D.4.1	Express	the	results	as	follows
--	-------	---------	-----	---------	----	---------

- toxic
- non-toxic

D.4.2 For assessment, see USP, chapter <88>.

Bibliography

- [1] ISO 11737-1:2006, Sterilization of medical devices Microbiological methods Part 1: Determination of a population of microorganisms on products
- [2] Ph.Eur., European Pharmacopeia, European Directorate for the Quality of Medicines, Council of Europe, Strasbourg, France

BSI — British Standards Institution

BSI is the independent national body responsible for preparing British Standards. It presents the UK view on standards in Europe and at the international level. It is incorporated by Royal Charter.

Revisions

British Standards are updated by amendment or revision. Users of British Standards should make sure that they possess the latest amendments or editions

It is the constant aim of BSI to improve the quality of our products and services. We would be grateful if anyone finding an inaccuracy or ambiguity while using this British Standard would inform the Secretary of the technical committee responsible, the identity of which can be found on the inside front cover. Tel: +44 (0)20 8996 9000. Fax: +44 (0)20 8996 7400.

BSI offers members an individual updating service called PLUS which ensures that subscribers automatically receive the latest editions of standards.

Buying standards

Orders for all BSI, international and foreign standards publications should be addressed to Customer Services. Tel: +44 (0)20 8996 9001. Fax: +44 (0)20 8996 7001. Email: orders@bsi-global.com. Standards are also available from the BSI website at http://www.bsi-global.com.

In response to orders for international standards, it is BSI policy to supply the BSI implementation of those that have been published as British Standards, unless otherwise requested.

Information on standards

BSI provides a wide range of information on national, European and international standards through its Library and its Technical Help to Exporters Service. Various BSI electronic information services are also available which give details on all its products and services. Contact the Information Centre. Tel: +44 (0)20 8996 7111. Fax: +44 (0)20 8996 7048. Email: info@bsi-global.com.

Subscribing members of BSI are kept up to date with standards developments and receive substantial discounts on the purchase price of standards. For details of these and other benefits contact Membership Administration.

Tel: +44 (0)20 8996 7002. Fax: +44 (0)20 8996 7001.

Email: membership@bsi-global.com.

Information regarding online access to British Standards via British Standards Online can be found at http://www.bsi-global.com/bsonline.

Further information about BSI is available on the BSI website at http://www.bsi-global.com.

Copyright

Copyright subsists in all BSI publications. BSI also holds the copyright, in the UK, of the publications of the international standardization bodies. Except as permitted under the Copyright, Designs and Patents Act 1988 no extract may be reproduced, stored in a retrieval system or transmitted in any form or by any means — electronic, photocopying, recording or otherwise — without prior written permission from BSI.

This does not preclude the free use, in the course of implementing the standard, of necessary details such as symbols, and size, type or grade designations. If these details are to be used for any other purpose than implementation then the prior written permission of BSI must be obtained.

Details and advice can be obtained from the Copyright & Licensing Manager. Tel: +44 (0)20 8996 7070. Fax: +44 (0)20 8996 7553. Email: copyright@bsi-global.com.

BSI 389 Chiswick High Road London

W4 4AL